NeRRe Therapeutics
Develops clinical and pre-clinical neurokinin receptor antagonists.
Launch date
Employees
Market cap
-
Enterprise valuation
€138m (Public information from Jul 2021)
Company register number 07916206
Stevenage England (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| EBITDA | (2.1m) | (9.1m) | (8.8m) | (11.8m) | (5.5m) | (6.4m) | (7.6m) |
| Profit | (1.2m) | (8.3m) | (12.1m) | (11.6m) | (6.5m) | (7.2m) | (8.8m) |
| R&D budget | - | 7.2m | 6.0m | 9.0m | 2.7m | 3.2m | 4.4m |
| Date | Investors | Amount | Round |
|---|---|---|---|
$18.4m | Series A | ||
£23.0m | Series B | ||
£20.0m Valuation: £115m -24.9x EV/LTM EBITDA | Series B | ||
| Total Funding | €68.3m | ||
Related Content
Recent News about NeRRe Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.